查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1495988

肿瘤消融市场：2024-2029 年预测

Tumor Ablation Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 124 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2022年肿瘤消融市值为12.91亿美元，预计复合年增长率为12.10%，到2029年市场规模将达到28.72亿美元。

通常用于治疗肺、肾、肝、骨等肿瘤和癌症的影像导引技术称为「肿瘤消融」。肿瘤消融技术的高效率和成本效益正在推动全球市场的需求。此技术通常透过冷冻、射频消融术和微波消融等不同方式进行。

肿瘤消融中采用的影像技术为早期肿瘤诊断和预防提供了有效的结果。癌症和肿瘤病例数的增加正在增加全球市场对肿瘤消融技术的需求。人们对癌症的认识不断提高，以及早期诊断和治疗癌症的需求正在推动这些技术在全球范围内的市场价值。

随着医疗机构和肿瘤医院的增多，肿瘤消融技术正变得越来越多的人能够接触到。诊断效率和成本效益正在提高肿瘤消融在全球市场的可接受性和应用。此外，领导企业在肿瘤消融研发领域的加大投入也为全球肿瘤消融市场的成长提供了机会。

政府和机构提供的支持也提高了肿瘤消融技术的可接受性和可用性。老年人口的增加和肿瘤发生率的增加也是推动全球肿瘤消融市场成长的关键因素之一。

市场驱动因素：

  • 癌症患者数量的增加预计将推动全球肿瘤消融市场的发展。

癌症病例数量的增加和癌症患者数量的增加是推动全球肿瘤消融市场成长的主要因素之一。人们的生活方式和现代饮食正在增加人们肿瘤和癌症的发生率。此外，肿瘤数量的增加也增加了全球市场对肿瘤消融等治疗和诊断方法的需求。

根据美国癌症协会的资料，美国每年诊断出约 1,762,450 例癌症和肿瘤新病例。癌症病例和癌症死亡率的上升正在推动美国市场对肿瘤消融的需求。根据美国癌症协会统计，美国有 606,880 人死于癌症。低效率的诊断和治疗技术导致全世界癌症和肿瘤死亡。

世界卫生组织（WHO）声称，经济不稳定的国家比经济稳定的国家有更多的肿瘤和癌症病例。国际癌症控制联盟 (IUCC) 指出，全世界六分之一的死亡是由于癌症或肿瘤造成的。据报道，在经济较不稳定和欠发达国家，癌症死亡率约 70%。对更好的诊断技术和治疗方法的需求正在推动全球肿瘤消融市场的发展。对肿瘤消融技术不断增长的需求和需求正在推动全球肿瘤消融市场的需求和市场价值。

  • 消融设备的技术进步将推动市场成长

消融设备研发技术的进步和升级正在刺激全球肿瘤消融市场的成长。多家公司的高额研发投资正在增加全球医疗保健和医疗领域肿瘤消融的全球市场占有率。此外，全球医疗保健和医疗领域的不断进步和开拓正在推动肿瘤消融技术市场达到一定水平。

冷冻消融、微波消融和其他技术的引入是推动全球肿瘤消融市场发展的某些发现。现代技术在癌症治疗和诊断的应用，将肿瘤消融技术提升到了新的水平。根据IUCC（国际癌症控制联盟）的报告，约1,670亿美元用于癌症治疗的研究和开发过程。

预计北美将主导市场。

预计北美地区将在预测年内主导全球肿瘤消融市场。该地区政府机构和多家公司增加对癌症治疗和诊断技术的投资是推动肿瘤消融市场成长的因素之一。

此外，北美国家肿瘤和癌症病例数量的增加以及老年人口比例的增加也是推动肿瘤消融市场成长的主要因素之一。

主要进展

  • 2023 年 12 月－Popular Equipment Finance 收购了 Quantum Surgical 的 Epione® 机器人。 Epione(R) 机器人是一个机器人平台，专为无法手术的腹部肿瘤的早期治疗而设计。 Epione(R) 在美国癌症中心使用，于 2023 年 5 月治疗了第一位癌症患者。 Quantum Surgical 是一家法国医疗机器人公司，透过标准化治疗提供一种新的癌症治疗方法。 Epione® 在欧洲获得了针对腹部和肺部肿瘤的 CE 标誌，并获得了 FDA 针对腹部肿瘤的批准。可在维勒瑞夫古斯塔夫·鲁西癌症中心和里昂临终关怀医院购买。 Epione® 已在全球治疗了 300 多名患者，积极的用户回馈加速了其在美国的采用。
  • 2023 年 3 月 - AngioDynamics 与 Minimax Medical 合作，进行产品系列的国际分销。此次合作包括 MiniMax Medical 的肿瘤和结节射频消融系统，并增强了 Angiodynamics 支持全球医疗保健部门改善患者生活的能力。 Minimax Medical 提供最具创新性的 RFA 设备，与 AngioDynamics 在肿瘤消融市场上的合作已超过 18 年。此次合作增强了 AngioDynamics 支援全球医疗保健产业改善患者生活的能力。 Minimax医疗控股集团是一家国际医疗科技集团，在多个领域提供微创医疗设备。
  • 2022 年 3 月 - Quantum Surgical 的 Epione® 机器人获得 FDA 510(k) 许可，这是一种用于微创肝癌治疗的机器人辅助技术。 Epione(R) 使临床医生能够进行安全有效的经皮肿瘤消融术，这是一种透过将针头插入皮肤来破坏肿瘤的微创治疗方法。 FDA 的 510(k) 许可授权 Epione® 介入肿瘤机器人在美国进行商业性销售和使用，以促进早期肝病治疗。 Quantum Surgical 计划将 Epione(R) 平台扩展到其他器官，并开发基于人工智慧的决策支援功能。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球肿瘤消融市场：依技术分类

  • 介绍
  • 射频 (RF) 消融术
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 微波消融
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 冷冻疗法
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他技术
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第六章全球肿瘤消融市场：依治疗方法分类

  • 介绍
  • 手术消融
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 腹腔镜消融术
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 经皮消融术
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第七章全球肿瘤消融市场：依应用分类

  • 介绍
  • 肝癌
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 肺癌
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 肾癌
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 骨转移
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他用途
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第八章全球肿瘤消融市场：按地区

  • 介绍
  • 北美洲
    • 依技术
    • 依治疗方法
    • 按用途
    • 按国家/地区
  • 南美洲
    • 依技术
    • 依治疗方法
    • 按用途
    • 按国家/地区
  • 欧洲
    • 依技术
    • 依治疗方法
    • 按用途
    • 按国家/地区
  • 中东/非洲
    • 依技术
    • 依治疗方法
    • 按用途
    • 按国家/地区
  • 亚太地区
    • 依技术
    • 依治疗方法
    • 按用途
    • 按国家/地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • Healthtronics, Inc.
  • Medtronic, PLC
  • Sonacare Medical
  • Boston Scientific Corporation
  • Edap TMS SA
  • Misonix, Inc.
  • Galil Medical, Inc.
  • Neuwave Medical, Inc.
  • Mermaid Medical A/S
  • Angiodynamics, Inc.
简介目录
Product Code: KSI061611901

The tumor ablation market was evaluated at US$1.291 billion in 2022 and is projected to grow at a CAGR of 12.10% to reach a market size of US$2.872 billion by 2029.

An image-guided technique generally employed for treating tumors and cancers in the lungs, kidneys, liver, bone, etc., is termed "tumor ablation". The high efficiency and cost-effectiveness offered by tumor ablation techniques are driving its demand in the global market. The technique is usually done by different means like cryoablation, radiofrequency ablation, microwave ablation, and others.

The imaging technique employed in tumor ablation provides efficient results in the diagnosis and prevention of tumors in their early stages. The rising cases of cancer and tumors are increasing the demand for tumor ablation techniques in the global market. The increasing awareness about cancer and the need to diagnose and treat cancer in its early stages is pushing the market value of these techniques globally.

The rise in the number of health and tumor-treating specialty hospitals is increasing the availability of tumor ablation techniques to people. Their efficiency in diagnosing and cost-efficiency are increasing the acceptability and applications of tumor ablation in the global market. The higher investment of major companies in the research and development sector of tumor ablation is also giving potential to the global tumor ablation market growth.

The support offered by governments and governmental agencies is also increasing the acceptability and availability of tumor ablation techniques. The growing geriatric population and the increasing rate of tumors are also some of the important factors driving the global tumor ablation market growth.

Market Drivers:

  • Rising cases of cancer are anticipated to propel the global tumor ablation market.

The rising cases of cancer and the increasing number of cancer patients are one of the major factors driving the global tumor ablation market growth. The lifestyle and modern diet of people have increased the rate of tumors and cancers in people. The rising cases of tumors have also resulted in the growing demand for treatment and diagnosis methods like tumor ablation in the global market.

The data from the American Cancer Society states that about 1,762,450 new cases of cancer or tumors are diagnosed in the United States each year. The rising cases of cancer and mortality rates due to cancer are increasing the demand for tumor ablation in the American market. The number of deaths due to cancer was reported as 606,880 in the United States by the American Cancer Society. Less efficient diagnosis and treatment techniques are resulting in cancer and tumor deaths around the world.

The WHO (World Health Organisation) claims that countries with less economic stability are showing more tumor and cancer cases compared to countries with high economic stability. The IUCC (International Union for Cancer Control) states that one in every 6 deaths around the globe is due to cancer or tumor. An approximate 70% mortality rate due to cancer is reported in countries with less economic stability and development. The need for better diagnosis techniques and treatment methods is boosting the global tumor ablation market. The rising need and demand for tumor ablation techniques are pushing the market demand and market value of the global tumor ablation market.

  • Technological advancements in ablation devices would bolster the market growth.

The technological advancements and up-gradation in research and development techniques employed in ablation devices are stimulating the global tumor ablation market growth. The high research and development investments made by several companies are raising the market share of the global tumor ablation market in the global healthcare and medical sector. The continuous up-gradation and developments in the healthcare and medical fields globally are also pushing the market for tumor ablation techniques to a certain level.

The introduction of cryoablation, microwave ablation, and other techniques has been certain discovery that has boosted the global market of tumor ablation. The application of the latest technologies in treating and diagnosing cancer has upgraded the techniques of tumor ablation to a new level. According to reports by IUCC (International Union for Cancer Control), about 167 billion USD is spent on the research and development process in cancer treatment.

North America is expected to dominate the market.

The North American region is expected to dominate the global tumor ablation market in the forecasted years. The increasing investments made by government organizations and several companies in this region in cancer treatment and diagnosis techniques are one of the factors boosting tumor ablation market growth.

The increasing cases of tumors and cancers and the increasing rate of the geriatric population in North American countries are also some of the major factors fuelling the market growth of the tumor ablation market.

Key Developments:

  • December 2023- Popular Equipment Finance acquired Quantum Surgical's Epione(R) robot, a robotic platform designed for early and curative treatment of inoperable abdomen tumors. The Epione(R) used by a US cancer center, where it treated the first cancer patient in May 2023. Quantum Surgical, a French medical robotics company, offers a new approach to cancer treatment by standardizing access to care. The Epione(R) is CE-marked in Europe for abdomen and lung tumors and FDA-cleared for abdominal tumors. It is available at Gustave Roussy Cancer Center in Villejuif and Hospices Civils de Lyon. Over 300 patients have been treated worldwide with Epione(R), and positive feedback from users helped accelerate its adoption in the US territory.
  • March 2023- AngioDynamics partnered with Minimax Medical for international distribution of its product portfolio. The partnership includes Minimax Medical's Radiofrequency Ablation System for tumors and nodules and enhances AngioDynamics' ability to support the healthcare sector in improving patients' lives globally. Minimax Medical, which offers some of the most transformative RFA devices, partnered with AngioDynamics for over 18 years in the tumor ablation market. The partnership strengthens AngioDynamics' ability to support the healthcare sector in improving patients' lives globally. Minimax Medical Holding Group is an international medical science and technology group that provides minimally invasive devices in various fields.
  • March 2022- Quantum Surgical received FDA 510(k) clearance for its Epione(R) robot, a robotic-assisted technology for minimally invasive liver cancer treatment. Epione(R) allows clinicians to perform safe and effective percutaneous tumor ablations, a minimally invasive treatment where a needle is inserted through the skin to destroy the tumor. The FDA 510(k) clearance permits the commercial sale and use of the Epione(R) interventional oncology robot in the United States to facilitate early-stage liver disease treatment. Quantum Surgical plans to extend the Epione(R) platform to other organs and develop artificial intelligence-based decision-support features.

Segmentation:

By Technology

  • Radiofrequency (Rf) Ablation
  • Microwave Ablation
  • Cryoablation
  • Other Technologies

By Mode of Treatment

  • Surgical Ablation
  • Laparoscopic Ablation
  • Percutaneous Ablation

By Application

  • Liver Cancer
  • Lung Cancer
  • Kidney Cancer
  • Bone Metastasis
  • Other Applications

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL TUMOR ABLATION MARKET BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. Radiofrequency (Rf) Ablation
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Microwave Ablation
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Cryoablation
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Other Technologies
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. GLOBAL TUMOR ABLATION MARKET BY MODE OF TREATMENT

  • 6.1. Introduction
  • 6.2. Surgical Ablation
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Laparoscopic Ablation
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Percutaneous Ablation
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. GLOBAL TUMOR ABLATION MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Liver Cancer
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Lung Cancer
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Kidney Cancer
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness
  • 7.5. Bone Metastasis
    • 7.5.1. Market Opportunities and Trends
    • 7.5.2. Growth Prospects
    • 7.5.3. Geographic Lucrativeness
  • 7.6. Other Applications
    • 7.6.1. Market Opportunities and Trends
    • 7.6.2. Growth Prospects
    • 7.6.3. Geographic Lucrativeness

8. GLOBAL TUMOR ABLATION MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Technology
    • 8.2.2. By Mode of Treatment
    • 8.2.3. By Application
    • 8.2.4. By Country
      • 8.2.4.1. USA
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Technology
    • 8.3.2. By Mode of Treatment
    • 8.3.3. By Application
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Technology
    • 8.4.2. By Mode of Treatment
    • 8.4.3. By Application
    • 8.4.4. By Country
      • 8.4.4.1. Germany
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. France
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. UK
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Others
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Technology
    • 8.5.2. By Mode of Treatment
    • 8.5.3. By Application
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Technology
    • 8.6.2. By Mode of Treatment
    • 8.6.3. By Application
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. India
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. Japan
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Taiwan
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Indonesia
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Healthtronics, Inc.
  • 10.2. Medtronic, PLC
  • 10.3. Sonacare Medical
  • 10.4. Boston Scientific Corporation
  • 10.5. Edap TMS S.A.
  • 10.6. Misonix, Inc.
  • 10.7. Galil Medical, Inc.
  • 10.8. Neuwave Medical, Inc.
  • 10.9. Mermaid Medical A/S
  • 10.10. Angiodynamics, Inc.